Full text
Earnings transcript
Read the complete earnings call transcript.
ORGO
Organogenesis Holdings Inc.
$0.89
0.06
(7.02%)
| Exchange: | NASDAQ |
| Market Cap: | 114.984M |
| Shares Outstanding: | 126.738M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Drug Manufacturers – Specialty & GenericView industry performance | |||||
| CEO: | Gary S. Gillheeney | |||||
| Full Time Employees: | 854 | |||||
| Address: |
| |||||
| Website: | https://organogenesis.com |
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis’s product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Click to read more…
Revenue Segmentation
Revenue by type
Industry Peers
| TICKER | COMPANY | MKT CAP | P/E | FWD P/E | ROIC |
|---|---|---|---|---|---|
| ORGO | Organogenesis Holdings Inc. | 115.0M | — | — | -8.1% |
 BGM | BGM Group Ltd. | 110.3M | — | — | -2.8% |
 OGI | Organigram Global Inc. | 133.8M | 2.1 | 2.3 | -13.7% |
 DERM | Journey Medical Corporation | 134.5M | — | — | -5.2% |
 ZYBT | Zhengye Biotechnology Holding Limited | 61.1M | — | — | -19.9% |
 RDHL | RedHill Biopharma Ltd. | 3.4M | — | — | 285.1% |
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 433,140 | 482,043 | 563,030 |
| Gross Profit | 326,659 | 366,302 | 425,508 |
| EBITDA | 36,031 | 15,763 | 73,908 |
| Operating Income | 12,525 | -1,283 | 55,869 |
| Net Income | 4,945 | 861 | 37,032 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 460,025 | 497,886 | 598,730 |
| Total Liabilities | 181,362 | 112,570 | 164,812 |
| Total Stockholders Equity | 278,663 | 385,316 | 300,129 |
| Total Debt | 119,351 | 43,312 | 82,137 |
| Cash and Cash Equivalents | 104,338 | 135,571 | 93,679 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 30,917 | 14,208 | -10,309 |
| Capital Expenditure | -24,364 | -10,032 | -14,151 |
| Free Cash Flow | 6,553 | 4,176 | -24,460 |
| Net Income | 4,945 | 861 | 37,032 |
| Net Change in Cash | 1,048 | 31,813 | -41,820 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2028 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 258,216.898 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 343,816.501 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 301,016.700 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | -10,167.271 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 687.630 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | -4,739.820 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | -31,477.133 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | -20,622.231 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | -26,049.682 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 153,792.360 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 204,774.946 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 179,283.653 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | -0.200 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | -0.160 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | -0.240 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 2 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 2 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates ORGO intrinsic value between $2.57 – $3.12 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about ORGO valuation
Is Organogenesis Holdings Inc. (ORGO) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Organogenesis Holdings Inc. (ORGO) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is ORGO a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ORGO trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is ORGO’s P/E ratio?
You can see ORGO’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for ORGO?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is ORGO a good long-term investment?
Whether ORGO fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
ORGO
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
7.02
Trading Metrics:
| Open: | 0.85 | Previous Close: | 0.84 | |
| Day Low: | 0.85 | Day High: | 0.9 | |
| Year Low: | 0.73 | Year High: | 7.08 | |
| Price Avg 50: | 1.32 | Price Avg 200: | 2.34 | |
| Volume: | 24409 | Average Volume: | 815500 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
